The global tumor necrosis factor inhibitor drugs market size is anticipated to reach USD 42.1 billion by 2026, according to a report published by Grand View Research, Inc. Increasing prevalence of autoimmune diseases, rapid technological advancements, and rise in healthcare expenditure across the globe are some of the major factors expected to drive the growth.
Currently,
there are five approved TNF inhibitor drugs in the market- Humira (adalimumab),
Enbrel (etanercept), Remicade (infliximab), Simponi/Simponi Aria (golimumab),
and Cimzia (certolizumab). Biosimilar versions of Humira, Enbrel, and Remicade
have been launched, causing a significant paradigm shift in the market.
The
wave of biosimilars pose a significant internal threat to the
biologics sale as biosimilars have a comparable efficiency as the original
products. The cost-effectiveness of biosimilars makes them an attractive choice
in economically sensitive areas. In addition, emerging countries, such as
India, China, and South Korea are active participants in the biosimilar market.
Some
of the key therapeutic areas involving treatment with TNF inhibitor drugs are
rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, and
ulcerative colitis. Although these medicines are mostly used for the treatment
of autoimmune diseases, several ongoing studies are investigating the role of
TNF inhibitors in the treatment of cancer and other inflammatory conditions.
Some
of the key players in the TNF inhibitor space are involved in strategic
initiatives, such as mergers and acquisitions and joint ventures for the
co-development of products. In addition, patent infringement issues between the
manufacturers makes the market dynamics intensely competitive. For instance,
AbbVie resolved an issue with Boehringer Ingelheim, regarding Humira’s intellectual
property (IP) rights. As per the terms of the agreement, Boehringer Ingelheim
received a non-exclusive license to Humira’s IP in the U.S.- scheduled to begin
in July 2023.
Full Research Report On Tumor Necrosis Factor Inhibitor Drugs Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/tumor-necrosis-factor-tnf-inhibitor-drugs-market
Further key
findings from the study suggest:
- Humira
accounted for nearly half the revenue share of TNF inhibitor drugs market
in 2018
- Emergence of
biosimilars is anticipated to be the major growth rendering driver for the
market
- Psoriasis is
projected to be the most rapidly growing application segment over the
forecast period
- Increased
adoption of e-commerce is a key driver for online pharmacies
- TNF
inhibitors faces an external threat from IL-inhibitors
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/tumor-necrosis-factor-tnf-inhibitor-drugs-market/request/rs1
Grand View Research has
segmented the global tumor necrosis factor inhibitor drugs market on the basis
of product, application, sales channel, and region:
TNF Inhibitor
Drugs Product Outlook (Revenue, USD Million, 2014 - 2026)
- Humira
- Enbrel
- Remicade
- Simponi/Simponi Aria
- Cimzia
- Biosimilars
TNF Inhibitor
Drugs Application Outlook (Revenue, USD Million, 2014 - 2026)
- Rheumatoid Arthritis
- Psoriasis
- Psoriatic Arthritis
- Crohn’s Disease
- Ulcerative Colitis
- Ankylosing Spondylitis
- Juvenile Idiopathic Arthritis
- Hidradenitis Suppurativa
- Others
TNF Inhibitor
Drugs Sales Channel Outlook (Revenue, USD Million, 2014 - 2026)
- Hospital Pharmacies
- Specialty Pharmacies
- Online Pharmacies
TNF Inhibitor
Drugs Regional Outlook (Revenue, USD Million, 2014 - 2026)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Spain
- France
- Italy
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment